Meet Dr. Thomas Wagner, the big shot behind Orbis Health Solutions, and a real-deal cancer researcher. This guy's on a mission – a mission to treat cancer without the nasty side effects that can be even worse than the cancer itself. It's like fighting fire with fire, but in a good way.
In an interview with ABC News, Wagner spilled the beans. Cancer isn't just about the bad news; it's also about the scary treatment. Imagine going through chemotherapy, a treatment that not only battles cancer but also takes down your good cells. That's a recipe for trouble, causing things like hair loss, feeling sick, and even messing up your immune system. Wagner saw people going through all of this and thought, "Nope, we need a better plan."
So, he set out to create a cancer treatment that doesn't bulldoze our immune system but actually uses its power. What did he come up with? A vaccine that's tailor-made for each person. This isn't your one-size-fits-all deal; it's like a personalized superhero suit.
Here's the science bit: Normally, cancer cells go incognito, tricking our immune system into thinking they're friendly. Sneaky, right? Wagner's solution is a genius move – enter the tumor lysate particle only (TLPO) vaccine. It snatches bits from the patient's tumor cells, shows them to the immune system, and says, "Hey, these are the troublemakers. Time to kick some cancer butt!" It's like giving our immune system a heads-up to spot and fight the cancer cells, just like it would with an infection.
Wagner dropped some wisdom bombs too: "People used to ask me, 'When's the cancer cure coming?' I've been in this game for 60 years, and I never had an answer. But now, in the last few years, things are looking up."
He believes this personalized vaccine could be the magic key to finally putting an end to cancer. But, and there's always a but, it needs a sidekick – early detection. Teaming up the vaccine with spotting cancer early might just be the superhero combo we've been waiting for.
In the world of cancer, Dr. Wagner might just be our hero, and his personalized vaccine? The secret weapon we've been hoping for all these years. Fingers crossed, folks.
A Closer Look at the Cancer Vaccine Making Waves
Wagner's TLPO cancer vaccine has undergone tests with hundreds of folks battling advanced melanoma in Phase 2 clinical trials.
Latest info from a conference spilled the beans - nearly 95% of those jabbed with only the vaccine were ticking after three years, and 64% were still keeping the disease at bay. For the serious stage III melanoma, the vaccine-only crowd boasted a 60% disease-free survival rate after three years, while the placebo bunch lagged at about 39%. Stage IV fighters with the vaccine showed about 68% disease-free survival, leaving the placebo group with a big fat zero.
Some usual suspects tagged along as side effects - a bit of redness or pain at the jab site, plus some post-jab fever and fatigue. Just your garden-variety vaccine reaction.
Dr. Vernon Sondak, a skin cancer doc at Moffit Cancer Center, gave a thumbs-up to the results. Still, he's got his skeptic hat on, reminding us that Phase 2 trials don't seal the deal. The big guns - Phase 3 clinical trials - need to step in and give a final verdict on whether this cancer vaccine is the superhero it claims to be.
Sondak spills the tea, "We've seen promises in Phase 2 deflate in Phase 3." It's like, don't count your chickens before they hatch.
With the nod from the Food and Drug Administration (FDA), Wagner's vaccine is getting the green light for a Phase 3 dance. A three-year shindig is on the horizon, hoping to rope in 500 players. Riley Polk, Orbis Health Solutions prez, spills the deets to WLOS, an ABC News buddy in Asheville, North Carolina.
Polk's got skin in the game. His pops battled cancer like a champ, tried Wagner's vaccine, and lived a decade more. When the end came, it wasn't cancer that threw the punch. Polk's take? "You can't tell me [the vaccine] doesn't work."
So, it's a wait-and-watch game. The big guns are gearing up for the final showdown, and folks like Polk are betting their chips on this vaccine. Here's to hoping it's the game-changer we've been waiting for. Cheers to more years!
Overcoming Financial Hurdles in the Quest for a Breakthrough Cancer Treatment
According to Polk, the Phase 3 clinical trial on the horizon is a whopping $100 million venture. For big-shot pharmaceutical companies swimming in funds and those cozying up to venture capitalists, that might be pocket change. However, for smaller, private players, it's a mountain to climb. Polk highlights the struggle, emphasizing how this financial hurdle handcuffs these companies, limiting their potential to delve into more clinical trials that could broaden the scope of Wagner's cancer vaccine.
To sidestep this financial roadblock and push this treatment to a broader audience, Wagner and his squad have initiated what's called a basket trial. This FDA-approved clinical trial lets them test the same vaccine that rocked the melanoma trials on anyone with a solid tumor, given they meet specific criteria. Wagner notes that participants in this trial should have a low or minimal tumor burden, often having undergone some form of treatment before taking the vaccine.
The first person to roll up their sleeve for this basket trial was Catie King, an Asheville native grappling with ovarian cancer for six years. WLOS reports that King felt fantastic after the initial round, experiencing only some redness at the injection site but no other side effects. Wagner poses a thought-provoking question, "How many people can say they feel better because of cancer therapy?" He shares anecdotal stories of patients feeling better, some even energized, after starting treatment with this vaccine.
For King, a part of the farming industry, the absence of side effects translates to a meaningful impact on her daily life, keeping her routine untouched.
"With this vaccine, there haven't been any hard days," King attests, highlighting the stark difference from her previous stint with low-dose chemotherapy.
Polk adds that seven others, battling brain, lung, and breast cancer, have received the vaccine through the basket trial. Over the past two decades, hundreds more have undergone this vaccine or its precursor.
Enter Mary Carol Abercrombie, a patient Wagner believes holds the record for one of the longest survivors once diagnosed with stage 4 melanoma. In 2001, Abercrombie completed a grueling year of cancer treatment with brutal side effects. Her doctors, expecting the worst, suggested she "just enjoy Christmas." Abercrombie, desperate for a lifeline, signed up for Wagner's cancer vaccine through her surgical oncologist's connection.
"Sign me up, 'cause there wasn't anything [else] out there," Abercrombie recalls, hoping to witness her son's wedding that year. More than two decades later, Abercrombie not only attended her son's wedding but is witnessing her four grandchildren grow up.
Before this vaccine becomes widely accessible for melanoma treatment, it needs to prove its mettle over years in a Phase 3 clinical trial and secure the FDA's final nod. To broaden its reach even more, success in the basket trial is crucial, followed by specific clinical trials for various indications, a journey demanding both years and millions of dollars.
Polk is optimistic that data from the basket trial will catch the eye of big pharmaceutical players. Through partnerships and alternative funding avenues, they might pave the way for more extensive FDA-backed trials.
Dr. Jade A Cobern, MD, MPH, a certified pediatrician specializing in preventive medicine, and Justin Berger, a reporter with WLOS, an ABC News affiliate in Asheville, North Carolina, have contributed to this insightful report.
deebo samuel injury, colon cancer symptoms, brian barczyk pancreatic cancer, sloan kettering, orbis health solutions, clinical trials gov, orbis health solutions stock, cancer vaccine, orbis health stock, cancer vaccine phase 3, cancer vaccine news
Nice post and it is helpful to us
ReplyDelete